Nano-Cap BriaCell Confirms Full Resolution Of Lung Metastasis In Breast Cancer Trial, Stock Shoots Higher
1. BCTX reported complete resolution of lung metastasis in its Phase 1/2 study. 2. Bria-OTS monotherapy achieved 100% tumor resolution in the treated patient. 3. Stable disease was confirmed four months into the therapy. 4. Patient enrollment for pivotal Phase 3 study has exceeded 100 participants. 5. BCTX stock rose 65%, reaching $8.96 in premarket trading.